IgG4 antibodies are unique to humans. IgG4 is associated with tolerance during immunotherapy in allergy, but also with pathology, as in pemphigus vulgaris and IgG4-related disease. Its induction is largely restricted to non-microbial antigens, and requires repeated or prolonged antigenic stimulation, for reasons poorly understood.An important aspect in generating high-affinity IgG antibodies is chemokine receptormediated migration of B cells into appropriate niches, such as germinal centers.Here, we show that compared to IgG1 B cells, circulating IgG4 B cells express lower levels of CXCR3, CXCR4, CXCR5, CCR6, and CXCR7, chemokine receptors involved in germinal center reactions and generation of long-lived plasma cells. This phenotype was recapitulated by in vitro priming of naive B cells with an IgG4inducing combination of T FH /T H2 cytokines. Consistent with these observations, we found a low abundance of IgG4 B cells in secondary lymphoid tissues in vivo, and the IgG4 antibody response is substantially more short-lived compared to other IgG subclasses in patient groups undergoing CD20 + B cell depletion therapy with rituximab. These results prompt the hypothesis that factors needed to form IgG4 B This article is protected by copyright. All rights reserved. cells restrain at the same time the induction of a robust migratory phenotype that could support a long-lived IgG4 antibody response. IgG4 B cells express fewer chemokine receptors involved in germinal center reactions and generation of long-lived plasma cells.This might restrain induction of a robust migratory phenotype that could support a long-lived IgG4 antibody response.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.